US Bioservices selected by Clovis Oncology to dispense RUBRACA


December 20, 2016

image

Frisco, Texas – US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced today it has been selected by Clovis Oncology to dispense RUBRACA® (rucaparib). RUBRACA was approved by the U.S. Food and Drug Administration on December 19, 2016, for the treatment of patients with ovarian cancer who have deleterious BRCA-mutated tumors – inclusive of both germline and somatic BRCA mutations – and have been treated with two or more chemotherapies.

Ovarian cancer is the fifth-leading cause of cancer-rel